NCT00977483已完成3 期
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 460
- 试验地点
- 38
- 主要终点
- Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint
研究概览
简要总结
To assess clinical efficacy and safety of long-term orally administered thioctic acid in the treatment of diabetic polyneuropathy.
详细描述
Stage 1 or 2a diabetic (poly)neuropathy (DNP) (Appendix 3) in patients with diabetes mellitus (type I or II); neuropathy impairment score of the lower limbs, enlarged by 7 objective items (NISLL+7) ≥ 97.5 percentile (corresponding to 4.43 score points); total symptoms score of the feet (TSSfeet) ≤ 5.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent. Patients must have willingness and complete competence to cooperate and language barriers must not preclude adequate understanding
- •Diabetes mellitus (Type I or II), as defined by the American Diabetes Association 1997, lasting > 1 year
- •Males or females 18 to 64 years (older patients are excluded because of age-related changes in reflexes, quantitative sensory testing endpoints, and nerve conduction endpoints)
- •Patient must have a symmetric sensory-motor peripheral polyneuropathy attributable to diabetes mellitus following a thorough evaluation for other causes of neuropathy determined by performing complete medical and neurological examinations including physical and neurological history, history of medications, history of exposure to other toxins, and laboratory studies
- •Severity of diabetic polyneuropathy must be Stage 1 or 2a
- •Insulin regimen, weight, diet, and activity level must be relatively stable in the opinion of the investigator (for example, HbA1C must not vary by more than ± 2 Vol.% within 6 months preceding the study i.e. if the index measure = 10% the range would be 8-12%)
- •NIS[LL]+7 tests ≥ 97.5 percentiles (corresponding to 4.43 transformed score points)
- •NIS[LL] ≥ 2 points (NIS[LL] is based on questions 17-24, 28, 29, 34, 35, and 37 of the NIS)
- •One of the following:
- •an abnormality of nerve conduction attributes in two separate nerves, i.e. ≥99th percentile for DL or ≤1st percentile for NCV or amplitude or
- •an abnormality of HRDB, i.e. ≤ 1st percentile
- •TSS (feet) ≤5
- •Females must either be surgically sterilised (tubal ligation, bilateral oophorectomy, or hysterectomy) or at least 1 year postmenopausal or practicing an acceptable method of contraception, including oral contraceptives with a stable regimen for at least two months, depo-medroxyprogesterone, a barrier method alone (diaphragm, condoms, or contraceptive sponge with spermicidals), or an IUD that has been in place for at least two months
排除标准
- •Patients with proximal asymmetric neuropathy, cranial neuropathies, truncal radiculopathy, pan dysautonomia, diabetic plexopathies, or acute or active mononeuropathies (including cranial neuropathies, post-herpetic neuralgias, etc.), the presence of which might obscure accurate assessment of severity of the diabetic polyneuropathy under assessment, with the exception of carpal tunnel syndrome (CTS) or tardy ulnar neuropathy (TUN) or both
- •Neuropathy of any cause other than diabetes mellitus which might interfere with the assessment of the severity of dPNP Other neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms or test abnormality which might interfere with the assessment of the severity of dPNP Myopathy of any cause which might interfere with the assessment of the severity of dPNP
- •Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers or limb ischemia
- •Patients with a history of ophthalmological findings suggesting a high risk for visual loss i.e., significant maculopathy or proliferative retinopathy
- •Psychiatric, psychological, or behavioural symptoms that would interfere with the patient's ability to participate in the trial
- •Patients with any active neoplastic disease except basal cell carcinoma
- •Patients with atrial fibrillation unless controlled and stabilised by medication (changed to this criterion by Amendment 1)
- •Patients with clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or endocrine disease (other than diabetes) that may confound interpretation of the study results or prevent the patient from completing the study
- •Patients who have had organ transplants of any kind
- •Patients with significant hepatic or renal disease (ASAT or ALAT >2 times normal, serum creatinine >1.8 mg/dL (>159 µmol/l) for males or >1.6 mg/dL (>141 µmol/l) for females)
- •Patients with a recent history (within last 12 months) of drug or alcohol abuse
- •Use of any investigational drug within the last 6 months
- •History of severe or anaphylactic reaction to multiple drugs, sulfur products, or biologic products (changed to this criterion by Amendment 1)
- •Ketoacidosis or hypoglycaemia within last 3 months resulting in hospital admission
- •Antioxidant therapy (vitamins E > 400IU, C > 200mg, and beta-Carotene > 30mg) or pentoxyphylline within last 1 month before start of trial
- •Use of evening primrose oil or any other gamma-linolenic acid containing substance within the last 3 months
- •Use of thioctic acid > 50mg/day within last 3 months
- •History of use of medications or vitamins known to cause peripheral neuropathy including but not limited to use of phenytoin or carbamazepine over 15 or more years, or use of pyridoxine > 100mg/d within the past 12 months
- •Bilateral sural nerve biopsies
- •Existing foot ulcers
- •Pregnant or lactating females
- •Continued use of medications listed in protocol 6.3.3 (first paragraph)
- •Medication non-compliance (deviation of more than ±10% of dosages to be taken (1 tablet/day))
研究组 & 干预措施
Drug: Thioctic Acid
Experimental
600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
干预措施: Thioctic Acid (Drug)
Drug: Placebo
Placebo Comparator
1 tablet once daily throughout the trial
干预措施: Placebo (Drug)
结局指标
主要结局
Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint
时间窗: 4 years
次要结局
- NIS, NSC, TSS, LLF, QST, VDT, CDT and HP, QAE by means of the HRDB, amplitude CMAP, DL and MNCV on peroneal and tibial nerves, amplitude SNAP and latency on sural nerve, foot inspection, efficacy.(4 years)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
3 期
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)Diabetic PolyneuropathyNCT00328601MEDA Pharma GmbH & Co. KG170
已完成
不适用
Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial MyopathyMitochondrial MyopathyNCT00004770National Center for Research Resources (NCRR)1
已完成
1 期
Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach.Acute Coronary SyndromeNCT03017963University Medical Center Groningen18
已完成
1 期
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's DiseaseAlzheimer Disease, Early OnsetNCT04552795The University of Texas Health Science Center at San Antonio12
进行中（未招募）
1 期
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)amyotrophic lateral sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002722-22-ITIRCCS ISTITUTO CLINICO HUMANITAS440